Saturday 22.10.2016

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 08:30–12:00
Hematology Educational

Hematology Educational

Room:Großer Saal
Session details 09:00–10:30
Workshop 1 (Parallel Sessions)

New Concepts of Radiation Field Design, Advanced Technologies and New Normal Organ Constraints

Room:Isabellensaal
  • 09:00

    Radiation eld reduction beyond ISRT? – options and concerns

  • Avoidance of organs at risk / dose-volume constraints – deep inspiration breath hold: techniques and daily monitoring

  • Avoidance of organs at risk / dose-volume constraints – dose / volume constrains for key organs at risk

Session details 09:00–10:30
Workshop 2 (Parallel Sessions)

Epidemiology and Registry Data

Room:Kleiner Saal
  • 09:00

    Welcome and short introduction

  • Experience from the international T cell project

  • Registry studies on Hodgkin Lymphoma – the US experience

  • Registry-based studies on socio-economic impact on outcome in Hodgkin Lymphoma in Brazil

  • Registry-based studies on pregnancy in Hodgkin Lymphoma patients

  • Registry-based research – pros and cons – the statistician’s view

  • General discussion

Session details 10:45–12:15
Workshop 3 (Parallel Sessions)

Pathology and Pathogenesis

Room:Isabellensaal
  • 10:45

    Risk and prognosis in Hodgkin Lymphoma and associations with an active, innate or anergic tumor immune response

  • NF-KB / IRF5 in Hodgkin Lymphoma

  • Noncoding RNAs and microRNA in Hodgkin Lymphoma

Session details 10:45–12:15
Workshop 4 (Parallel Sessions)

PET

Room:Kleiner Saal
  • 10:45

    Pretreatment stage or metabolic volume: which is better to direct treatment strategy?

  • Response assessment in the era of checkpoint inhibitors

Session details 12:45–13:45
Satellite Symposium

Recent Advances in the Treatment of Lymphoma

Room:Großer Saal
  • 12:45

    The FLASH project: establishing a novel surrogate endpoint in first-line FL

  • Update on clinical data of IMiDs® in the treatment of lymphoma

Session details 14:00–15:30
Workshop 5 (Parallel Sessions)

Biomarkers

Room:Großer Saal
  • 14:00

    Methodological issues of circulating cell-free DNA detection in HL

  • Outcome prediction of aSCT using Hodgkin Lymphoma relapse biopsies

  • Nanostring-based outcome prediction in HL patients treated with BEACOPP

  • Integration of IPS factors with gene expression for treatment outcome prediction

  • Biomarkers / companion diagnostics for checkpoint inhibition

Session details 14:00–15:30
Workshop 6 (Parallel Sessions)

Elderly Patients

Room:Kleiner Saal
Session details 14:00–15:30
Workshop 7 (Parallel Sessions)

GHSG Workshop

Room:Isabellensaal
Session details 16:00–17:30
Workshop 8 (Parallel Sessions)

Genetics and Microenvironment

Room:Großer Saal
Session details 16:00–17:30
Workshop 9 (Parallel Sessions)

NLPHL

Room:Isabellensaal
  • 16:00

    Update on classi cation of NLPHL and its distinction from TCRBCL and transformed DLBCL

  • Latest GHSG data on NLPHL

  • Case studies of patients with “apparent” relapse of NLPHL

Session details 16:00–17:30
Workshop 10 (Parallel Sessions)

Late Effects

Room:Kleiner Saal
  • 16:00

    Influence of radiotherapy and chemotherapy in modern Hodgkin Lymphoma treatment on risks of cardiovascular disease and second malignancy

  • Reducing cardiovascular risk in Hodgkin Lymphoma survivors – the SECURE trial

  • Phase 2 trial comparing the feasibility and efficacy of physical activity and multifactorial drug treatment in Hodgkin Lymphoma survivors

Session details 17:45–19:15
Satellite Symposium

Into the Future – New Treatment Options for Hematologic Malignancies

Room:Großer Saal
  • 17:45

    Welcome

  • 17:50

    Midostaurin – a novel therapeutic approach for patients with FLT3-mutated AML

  • 18:05

    The concept of treatment-free remission in CML – results from current studies

  • 18:20

    Panobinostat for relapsed or refractory myeloma: pan-HDAC-inhibition with epigenetic e ects

  • 18:35

    Advances in the treatment of hematologic malignancies: use of CAR T cells

Sunday 23.10.2016

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 07:30–08:30
Satellite Symposium

The Evolution of Chemotherapy: Using the A-DAC Principle to Unlock New Treatment Options in Hodgkin Lymphoma

Room:Großer Saal
  • 07:30

    The evolution of chemotherapy – an introduction from the chair

  • 07:35

    The A-DAC principle – introducing EDO-S101

  • 07:45

    Breaking through resistance – the potential for EDO-S101 (an overview of pre-clinical data in Hodgkin Lymphoma)

  • 08:05

    EDO-S101: pre-clinical data in Multiple Myeloma and initial ndings from phase I in haematological malignancies

  • 08:25

    Unlocking the potential – Q&A session

Session details 08:30–10:00
Scientific Session 1

Interactive Case Discussions

Room:Großer Saal
  • 08:30

    Case Discussion #1: Early Unfavorable - PET driven?

  • 08:50

    Case Discussion #2: HL during pregnancy

  • 09:10

    Case Discussion #3: Late Relapse of HL

  • 09:30

    Case Discussion #4: Relapsed/Refractory HL and PD-1i

Session details 10:30–12:00
Scientific Session 2

MRD and Prediction

Room:Großer Saal
Session details 12:15–13:45
Satellite Symposium

New Insights in the Treatment and Management of Lymphoid Malignancies

Room:Großer Saal
  • 12:15

    Welcome

  • 12:20

    Impact of febrile neutropenia in the HD18 trial: nal analysis of the project “daily G-CSF versus Peg lgrastim”

  • 12:35

    BiTE®: a new strategy for hematologic malignancies

  • 13:05

    Multiple Myeloma: new treatment options for patients with Car lzomib

  • 13:35

    Conclusion and closing remarks

Session details 14:00–15:30
Workshop 11 (Parallel Sessions)

Immunomodulation

Room:Kleiner Saal
  • 14:00

    Biological basis for PD-1 based immunotherapy

  • How do we rationally combine immune checkpoint therapy for optimal impact

  • Radiotherapy and immunotherapy combinations

  • Allo transplant vs checkpoint blockade in HL

Session details 14:00–15:30
Workshop 12 (Parallel Sessions)

Current Concepts in Allo TX

Room:Großer Saal
  • 14:00

    Allo-SCT in RR HL. The state of the art

  • The impact of the stem cell source (HLA id Sib vs MUD vs CB vs Haplo) in the outcome after allo-SCT

  • The role of allogeneic stem cell transplantation in the era of new drugs

Session details 14:00–15:30
Workshop 13 (Parallel Sessions)

Grey Zone Lymphoma

Room:Marsilius Saal
Session details 16:00–17:30
Satellite Symposium

Relapsed / Refractory Hodgkin Lymphoma: Nuances in Therapeutic Strategies to Improve Outcomes – a Case-Based Program

Room:Großer Saal
  • 16:00

    Welcome and introduction

  • 16:00

    Avoiding relapse of Hodgkin Lymphoma (HL): have we moved the needle?

  • 16:10

    Case #1: patient with advanced HL who relapses 18 months after initial therapy

  • 16:15

    Relapsed / refractory HL: therapeutic options prior to autologous stem cell transplant (ASCT)

  • 16:30

    Case #2: patient with bulky relapsed HL occurring 10 months following initial therapy

  • 16:35

    Post-ASCT relapse: making the most of what we have

  • 16:50

    Q&A

  • 16:55

    Case #3: patient with HL who has relapsed following ASCT

  • 17:00

    Novel agents in HL: what, how, and when should they be integrated?

  • 17:15

    Challenge the experts

  • 17:25

    prIME PointsTM

Session details 17:45–19:45
Main Program

Opening Ceremony

Room:Großer Saal
  • 17:45

    Movie: A History of Hodgkin Lymphoma

  • Key Note Lectue

  • Awards Ceremony

Session details 20:00
Main Program

Get Together

Room:Kleiner Saal

Monday 24.10.2016

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 07:30–08:30
Satellite Symposium

Future Directions in Lymphoma and Myeloma Therapy

Room:Großer Saal
  • 07:30

    Mode of action of PD1 / PD-L1 monoclonal antibodies in HL

  • 07:50

    Novel therapeutic strategies to improve outcome of patients with aggressive lymphomas

  • 08:10

    Targeting CD38 in Multiple Myeloma

Session details 08:30–10:30
Scientific Session 3

Biology and Microenvironment

Room:Großer Saal
  • 08:30

    Genetic lesions in HRS cells and their relationship to CD30+ B cells

  • 08:50

    Exome-sequencing in HL

  • 09:10

    Gene expression pro ling of the HL microenvironment

  • 09:30

    Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS

  • 09:40

    High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma

  • 09:50

    The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma

  • 10:00

    abstract talk Abstract Talk: T004 Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS

  • 10:10

    abstract talk Abstract Talk: T005 High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma

  • 10:20

    abstract talk Abstract Talk: T006 The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma

Session details 10:30–12:00
Scientific Session 4

Immunotherapy (Basic Science)

Room:Großer Saal
  • 10:30

    PD1 / PD-L1 / L2 assessment in HL

  • 10:50

    Mode of action of PD1 / PD-L1 MoAbs in HL

  • 11:10

    Other new approaches

  • 11:30

    Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion

  • 11:40

    CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro- tumor e ects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment

  • 11:50

    Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?

  • 12:00

    abstract talk Abstract Talk: T007 Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion

  • 12:10

    abstract talk Abstract Talk: T008 CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro-tumor effects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment

  • 12:20

    abstract talk Abstract Talk: T009 Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?

Session details 12:15–13:45
Satellite Symposium

Evolving Therapy in the HL Treatment Landscape

Room:Großer Saal
  • 12:15

    Welcome and introductions

  • 12:20

    Rationale for I-O therapies in solid and hematological malignancies

  • 12:35

    Balancing the risk-benefit ratio: current treatment regimens and unmet needs in HL

  • 13:00

    I-O in cHL: an eye towards the future

  • 13:25

    Audience Q&A session conclusions

Session details 14:00–15:30
Scientific Session 5

PET – Where Are We?

Room:Großer Saal
  • 14:00

    PET update 2016

  • 14:20

    WS report “Is PET as good as we think?”

  • 14:40

    Visual and quantitative PET / CT

  • 15:00

    Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and prognostic impact in Hodgkin Lymphoma: results from an international collaborative study

  • 15:10

    Strong predictive value of PET based metabolic tumor volume on survival after autologous HCT for Hodgkin Lymphoma

  • 15:20

    Semi-quantitative parameters to improve the interim FDG-PET / CT positive predictive value in Hodgkin Lymphoma

  • 15:30

    abstract talk Abstract Talk: T019 Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and prognostic impact in Hodgkin Lymphoma: results from an international collaborative study

  • 15:40

    abstract talk Abstract Talk: T020 Strong predictive value of PET based metabolic tumor volume on survival after autologous HCT for Hodgkin Lymphoma

  • 15:50

    abstract talk Abstract Talk: T021 Semi-quantitative parameters to improve the interim FDG-PET/CT positive predictive value in Hodgkin Lymphoma

Session details 16:00–17:30
Scientific Session 6

Early Stages

Room:Großer Saal
  • 16:00

    Early favorable HL: pros and cons of PET-adapted therapy

  • 16:20

    Early unfavorable: new standard of care?

  • 16:40

    NLPHL

  • 17:00

    Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial

  • 17:10

    Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience

  • 17:20

    Results of US intergroup trial of response-adapted chemotherapy or chemotherapy / radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB / Alliance 50604)

  • 17:30

    abstract talk Abstract Talk: T010 Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial

  • 17:40

    abstract talk Abstract Talk: T012 Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Session details 17:45–19:15
Satellite Symposium

Managing Hodgkin Lymphoma – A World View

Room:Großer Saal
  • 17:45

    Welcome and introduction

  • Diagnostics in practice: the ideal and the pragmatic

  • Prognostic indicators in front-line HL: a practical guide to individualizing therapy

  • Imaging and monitoring strategies: optimizing available resources

  • Optimizing HL management in the relapsed / refractory setting: making the most of available options

  • Concluding remarks

Tuesday 25.10.2016

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 07:30–08:30
Satellite Symposium

Ask the Expert: An Open Forum on Hodgkin Lymphoma

Room:Großer Saal
Session details 08:30–10:00
Scientific Session 7

Pediatric HL

Room:Großer Saal
  • 08:30

    Interim results of EuroNet-PHL-C1

  • 08:50

    Targeted agents in pediatric HL

  • 09:10

    COG / ECOG: AYA HL

  • 09:30

    Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/ A12707)

  • 09:40

    Phase III ABC study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children's Oncology Group

  • 09:50

    Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis

  • 10:00

    abstract talk Abstract Talk: T016 Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/A12707)

  • 10:10

    abstract talk Abstract Talk: T017 Phase III study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children’s Oncology Group

  • 10:20

    abstract talk Abstract Talk: T018 Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis

Session details 10:30–12:00
Scientific Session 8

Advanced Stages

Room:Großer Saal
  • 10:30

    Debate: PET-guided ABVD versus old school BEACOPP

  • 11:10

    Perspectives in advanced HL

  • 11:30

    BEACOPPescalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials

  • 11:40

    Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials

  • 11:50

    Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging,

  • 12:00

    abstract talk Abstract Talk: T001 BEACOPP escalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials

  • 12:10

    abstract talk Abstract Talk: T002 Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials

  • 12:20

    abstract talk Abstract Talk: T003 Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging

Session details 12:15–13:00
Satellite Symposium

Classification of New Therapeutic Options for CLL and Follicular NHL

Room:Großer Saal
Session details 13:00–13:45
Main Program

Poster Walk

Room:Kleiner Saal
Session details 14:00–15:30
Scientific Session 9

Relapsed HL

Room:Großer Saal
  • 14:00

    Brentuximab vedotin in relapsed HL

  • 14:20

    Clinical results with anti-PD(L)1 antibodies in HL

  • 14:40

    Role of allo-Tx in the PD1 era

  • 15:00

    CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation

  • 15:10

    Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study

  • 15:20

    TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study

  • 15:30

    abstract talk Abstract Talk: T022 CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation

  • 15:40

    abstract talk Abstract Talk: T023 Pembrolizumab for relapsed/refractory classical Hodgkin Lymphoma (R/R cHL): Multicohort, phase 2 KEYNOTE-087 study

  • 15:50

    abstract talk Abstract Talk: T024 TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin Lymphoma (HL). A phase 1 dose-escalation study

Session details 16:00–17:30
Scientific Session 10

Survivorship

Room:Großer Saal
Session details 17:45
Scientific Session 11

Closing Remarks

Room:Großer Saal

Basement

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Basement Wardrobe Go to Ground Floor Go to Ground Floor Basement

Ground Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Ground Floor Go to Basement Go to Basement Go to First Floor Go to First Floor Kleiner Saal Marsilius Saal Ground Floor

First Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of First Floor Go to Ground Floor Go to Ground Floor Großer Saal Isabellensaal First Floor

Exhibition

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Map of the exhibition. Map of the First Floor showing the location of 15 exhibitors. Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal

Biology and Microenvironment

Selected for Oral Presentation

  • Show Details

    P026 (P026) Hodgkin cell-derived extracellular vesicles shape fibroblast activity

    • Bösl T
    • Hansen HP
    • Engert A
    • Pogge von Strandmann E
  • Show Details

    P030 (P030) The lymphoid cell specific transcription factor ELF-1 is transcriptionally downregulated and recurrently deleted in classical Hodgkin lymphoma (cHL)

    • Giefing M
    • Zemke N
    • Bodnar M
    • Domanowska E
    • Janiszewska J
    • Paczkowska J
    • Ustaszewski A
    • Martin-Subero JI
    • Ammerpohl O
    • Klapper W
    • Marszalek A
    • Siebert R
  • Show Details

    P036 (P036) Tightly regulated FOXO3 expression is critical for the maintenance of cHL

    • Weitzer CD
    • Xie L
    • Guan H
    • Herrmann F
    • Pick S
    • Wirth T
    • Ushmorov A
  • Show Details

    T004 (T004) Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS

    • Mata E
    • Díaz-López A
    • Montalban C
    • Fernandez R
    • Bellas C
    • Burgos F
    • Mestre MJ
    • Menárguez J
    • Provencio M
    • Santonja C
    • Piris MA
    • Garcia JF
  • Show Details

    T005 (T005) High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma

    • Hollander P
    • Peter P
    • Smedby KE
    • Enblad G
    • Mortensen J
    • Amini RM
    • d´Amore F
    • Molin D
    • Glimelius I
  • Show Details

    T006 (T006) The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma

    • Lollies A
    • Hartmann S
    • Schneider M
    • Bracht T
    • Arnolds J
    • Klein-Hitpass L
    • Sitek B
    • Hansmann ML
    • Küppers R
    • Weniger MA

Posters

  • Show Details

    P024 (P024) Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma

    • Wurster KD
    • Hummel F
    • Richter J
    • Giefing M
    • Hartmann S
    • Hansmann ML
    • Kreher S
    • Köchert K
    • Krappmann D
    • Klapper W
    • Hummel M
    • Wenzel S
    • Lenz G
    • Janz M
    • Dörken B
    • Siebert R
    • Mathas S
  • Show Details

    P025 (P025) Determination of the mutational landscape of primary Hodgkin and Reed/Sternberg cells of classical Hodgkin lymphoma

    • Schneider M
    • Döring C
    • Czeschik JC
    • Lollies A
    • Hartmann S
    • Rahmann S
    • Hansmann ML
    • Küppers R
  • Show Details

    P027 (P027) Prognostic implications of an active, innate or anergic immune response in the Hodgkin lymphoma tumor microenvironment

    • Hollander H
    • Rostgaard K
    • Smedby KE
    • Molin D
    • Loskog A
    • de Nully Brown P
    • Enblad G
    • Amini RM
    • Hjalgrim H
    • Glimelius I
  • Show Details

    P028 (P028) Studying the role of oncogenic miR-24-3p in Hodgkin lymphoma

    • Yuan Y
    • Kluive Jr
    • Koerts J
    • de Jong D
    • Rutgers B
    • Diepstra A
    • Visser L
    • van den Berg A
  • Show Details

    P029 (P029) Characterization of Hodgkin lymphoma clonogenic cells using a new L428 in vivo xenograft model in immunodeficient NOD/SCID-gammac-/- mice and peripheral lymphocytes study in Hodgkin Lymphoma patients

    • Cuceu C
    • Al Jawhari M
    • Morat L
    • Frenzel M
    • Lewandowski D
    • Junker S
    • Pflumio F
    • Bourhis J
    • Girinsky T
    • Sabatier L
    • Carde P
    • M’kacher R
  • Show Details

    P031 (P031) Mutations in CD58 and MYB in Hodgkin lymphoma

    • Abdul Razak FR
    • Diepstra A
    • Jong D
    • Koerts J
    • Rutgers B
    • Kluiver J
    • Visser L
    • van den Berg A
  • Show Details

    P032 (P032) Re-fusion of small mononucleated Hodgkin cells leads to giant multinucleated Reed-Sternberg cells in Hodgkin lymphoma

    • Rengstl B
    • Newrzela S
    • Heinrich T
    • Weiser C
    • Thalheimer FB
    • Schmid B
    • Warner K
    • Hartmann S
    • Schroede Tr
    • Küppers R
    • Rieger MA
    • Hansmann ML
  • Show Details

    P033 (P033) Molecular characterization of Bruton’s Tyrosine Kinase Inhibitor in Hodgkin’s Lymphoma: Cellular and Animal Models

    • Muqbil I
    • Aboukameel A
    • Azmi AS
    • Mohammad RM
    • Ramchandren R
  • Show Details

    P034 (P034) Functional analysis to elucidate the susceptibility mechanisms of SNPs at the REL, GATA3 and TCF3 loci in classical Hodgkin Lymphoma

    • Veenstra R
    • Kluiver J
    • de Jong D
    • Koerts J
    • Visser L
    • Diepstra A
    • van den Berg A
  • Show Details

    P035 (P035) IGH-mediated translocations, recurrent in classic Hodgkin lymphoma, frequently correlate with an aggressive behavior

    • Wlodarska I
    • Dierickx D
    • Pluys U
    • Doms K
    • Graux C
    • Van Hoof A
    • Vandenberghe P
    • Michaux L
    • Tousseyn T
  • Show Details

    P037 (P037) In-Vitro and In-Vivo preclinical activity of EDO-S101 in Hodgkin lymphoma

    • Al Jawhari M
    • Cuceu C
    • Frenzel M
    • Stimmer L
    • Junker S
    • Bosq J
    • Carde P
    • Mehrling T
    • Sabatier L
    • Pflumio F
    • M’kacher R
  • Show Details

    P038 (P038) Hodgkin Reed-Sternberg cells in classical Hodgkin lymphoma are surrounded by T regulatory cells while lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma are surrounded by T follicular helper cells

    • Visser L
    • Sattarzadeh A
    • Wu R
    • Rutgers B
    • Diepstra A
    • van den Berg A
  • Show Details

    P039 (P039) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients exposed for granulocyte-colony stimulating growth factor

    • Andersen MD
    • Kamper P
    • d’Amore A
    • Clausen M
    • Bentzen H
    • d'Amore F
  • Show Details

    P040 (P040) Correlation between pre-treatment level of soluble PD-L1 and outcome in classical Hodgkin lymphoma included in a prospective study of the Lymphoma Study Association (LYSA)

    • Ghesquieres H
    • Drouet Y
    • Azzaoui I
    • Rossille D
    • Rossi C
    • Roussel M
    • Salles G
    • Traverse-Glehen A
    • Casasnovas O
    • Fest T
  • Show Details

    P041 (P041) Proteasome Inhibitor Therapy (PIT) in Hodgkin Lymphoma (HL): Leveraging Systems Biology Analyses (SBA) for Cell-Specific Transcriptome Alterations and Optimum Combinatorial Therapy

    • Passero Jr. FC
    • Beheshti A
    • Dashnamoorthy R
    • Evens AM
  • Show Details

    P042 (P042) Telomere maintenance mechanisms and Tumor microenvironment are key factors in the outcome of classic Hodgkin lymphoma

    • M’kacher R
    • Cuceu C
    • Morat L
    • Al Jawhari M
    • Frenzel M
    • Shim G
    • Lenain A
    • Ricoul M
    • Hempel W
    • Guilotto E
    • Junker S
    • Girinsky T
    • Badie C
    • Colicchio B
    • Dieterlen A
    • Jeandidier E
    • Moralès O
    • Renaud S
    • Van de Wyngaert Z
    • Carde P
    • Delhem N
    • Sabatier L
  • Show Details

    P043 (P043) Phenotypic characterization of circulating lymphocytes in Hodgkin´s lymphoma (HL) with focus on T cells

    • Palma M
    • Heimersson K
    • Näsman-Glaser B
    • Hansson L
  • Show Details

    P044 (P044) SIP-F1: A new gray zone lymphoma cell line?

    • Rengstl B
    • Hartmann S
    • Eberth S
    • Döring C
    • Pommerenke C
    • Becker PSA
    • Weiser C
    • Warner K
    • Doering C
    • Seidl C
    • Küppers R
    • Abken H
    • MacLeod RA
    • Drexler HG
    • Hansmann ML
    • Newrzela S
  • Show Details

    P045 (P045) CD4 lymphopenia as a prognosis factor in previously untreated Hodgkin lymphoma

  • Show Details

    P046 (P046) Can plasma chemokines and soluble receptor monitoring predict outcome in classical Hodgkin’s Lymphoma (cHL) patients?

    • Stamatoullas A
    • Perdrix A
    • Lemasle E
    • Thill C
    • Camus V
    • Veresezan L
    • Picquenot JM
    • Menard AL
    • Lenain P
    • Contentin N
    • Lanic H
    • Lepretre S
    • Brehar O
    • Cardinael N
    • Fontura ML
    • Fronville C
    • Jardin F
    • Bastard C
    • Tilly H
  • Show Details

    P047 (P047) Expression and prognostic impact of indoleamine 2,3-dioxygenase in Hodgkin’s lymphoma

    • Kryachok I
    • Novosad O
    • Skrypets T
    • Ulianchenko K
    • Tytorenko I
    • Khranovska N
    • Skachkova O
    • Svergun N
    • Gorbach O
  • Show Details

    P048 (P048) Reed-Sternberg Cells on Bone Marrow Cytology: The Very Early Feature on Hemophagocytic Lymphohistiocytosis Associated to Hodgkin Lymphoma

    • Niero-Melo L
    • Lustri LA
    • Polegatto BF
    • Del Castanhel C
    • Cantadori LO
    • Oliveira CC
    • Gaiolla RD
  • Show Details

    P048B (P048B) A novel PTPN1 splice variant regulates JAK/STAT activity in classical Hodgkin’s lymphoma cells

    • Zahn M
    • Marienfeld R
    • Melzner I
    • Heinrich J
    • Rehm A
    • Barth TF
    • Dorsch K
    • Brüderlein S
    • Möller P

Early Stages

Selected for Oral Presentation

  • Show Details

    T010 (T010) Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial

    • Sasse S
    • Bröckelmann PJ
    • Görgen H
    • Plütschow A
    • Mueller H
    • Kreissl S
    • Bürkle C
    • Borchmann S
    • Fuchs M
    • Borchmann P
    • Engert A
  • Show Details

    T012 (T012) Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

    • Straus DJ
    • Pitcher B
    • Kostakoglu L
    • Grecula JC
    • Hsi ED
    • Schoder H
    • Jung SH
    • Popplewell LL
    • Chang JE
    • Moskowitz CH
    • Wagner-Johnson N
    • Leonard JP
    • Friedberg JW
    • Kahl BS
    • Cheson BD
    • Bartlett NL

Posters

  • Show Details

    P049 (P049) Long-Term Follow-Up of Contemporary Treatment in Early-Stage Unfavorable Hodgkin Lymphoma (HL): Updated Analyses of the German Hodgkin Study Group HD8 and HD11 Trial

    • Sasse S
    • Bröckelmann PJ
    • Görgen H
    • Plütschow A
    • Mueller H
    • Kreissl S
    • Bürkle C
    • Borchmann B
    • Fuchs M
    • Borchmann P
    • Engert A
  • Show Details

    P050 (P050) Final Results of a Quality Assurance Program within the German Hodgkin Study Group HD13/14 trial – A report from the radiotherapy reference panel integrating modern guidelines

    • Eich HT
    • Kriz J
    • Plütschow A
    • Engenhart-Cabillic R
    • Haverkamp U
    • Herfarth K
    • Lukas P
    • Schmidberger H
    • Staar S
    • Baues C
    • Fuchs M
    • Engert A
  • Show Details

    P051 (P051) Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x 2 cycles followed by PET/CT restaging and 20 Gy of involved-site radiotherapy

    • Kamran SC
    • Jacene HA
    • Chen YH
    • Mauch PM
    • Ng AK
  • Show Details

    P052 (P052) Optimized “butterfly” VMAT reduces mean dose to coronary arteries for early stage HL patients undergoing mediastinal radiotherapy

    • Filippi AR
    • Levis M
    • Girardi A
    • Fiandra C
    • Piva C
    • Donegani I
    • Ragona R
    • Ricardi U
  • Show Details

    P053 (P053) Biological evaluation in the treatment planning. Is there a use for patients with Hodgkin’s Lymphoma?

    • Kriz J
    • Haverkamp U
    • Pepper N
    • Elsayad K
    • Kröger K
    • Reinartz G
    • Glashörster M
    • Kittel C
    • Eich HT
  • Show Details

    P054 (P054) The effect of deep inspiration breath hold (DIBH) Intensity-Modulated Radiation Therapy (IMRT) on sparing healthy tissues in the treatment of lymphoma involving the mediastinum

    • Eastman B
    • Uhl J
    • Mosienko V
    • Murphy J
    • Sanghvi P
  • Show Details

    P055 (P055) Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era

    • Gotti M
    • Merli F
    • Re A
    • Rusconi C
    • Pulsoni A
    • Rigacci L
    • Merli M
    • Liberati M
    • Ferretti V
    • Zoboli V
    • Fama A
    • Dalceggio D
    • Meli E
    • Annechini G
    • Puccini B
    • Ferrario A
    • Appolloni V
    • Sciarra R
    • Frigeni M
    • Arcaini L
    • Bonfichi M
  • Show Details

    P056 (P056) Construction of a Decision Model to Aid Treatment Choices for Early Stage Hodgkin Lymphoma (ES HL): Bringing Survivorship Forward

    • Kelly MJ
    • Parsons SK
    • Cohen JT
    • Castellino SM
    • Kelly KM
    • Keller F
    • Henzer TJ
    • Kumar A
    • Johnson P
    • Meyer RM
    • Morton LM
    • Radford J
    • Raemaekers J
    • Hodgson DC
    • Evens AM
  • Show Details

    P057 (P057) Doses to organs at risk at different modes of 3D-conformal radiotherapy for mediastinal stage II Hodgkin Lymphoma (HL)

    • Ilyin NV
    • Vinogradova JN
    • Ivanova EI
  • Show Details

    P058 (P058) Residual site radiation therapy (RS RT): An opportunity to increase safety of combined modality therapy (CMT) for early stage Hodgkin lymphoma (HL)

    • Straus DJ
    • Cahlon O
  • Show Details

    T011 (T011) Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience

    • Dedeckova K
    • Mocikova H
    • Markova J
    • Gaherova L
    • Kantorova I
    • Ondrova B
    • Vondracek V
    • Vitek P
    • Kubes J

Advanced Stages

Selected for Oral Presentation

  • Show Details

    T001 (T001) BEACOPP escalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials

    • von Tresckow B
    • Kreissl S
    • Haverkamp H
    • Sasse S
    • Diehl V
    • Engert A
    • Borchmann P
  • Show Details

    T002 (T002) Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials

    • André M
    • Fortpied C
    • Viviani S
    • Bellei M
    • Carde P
    • Hutchings M
    • Gianni A
    • Brice P
    • Casasnovas O
    • Gobbi P
    • Zinzani PL
    • Dupuis J
    • Iannitto E
    • Rambaldi A
    • Brière J
    • Perrot A
    • Heczko M
    • Valagussa P
    • Douxfils J
    • Joubert C
    • Federico M
    • Mounier N
  • Show Details

    T003 (T003) Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging

    • Friedberg JW
    • Li H
    • Schöder H
    • Straus DJ
    • Moskowitz CH
    • LeBlanc M
    • Rimsza LM
    • Bartlett NL
    • Evens AM
    • Mittra ES
    • LaCasce AS
    • Sweetenham JW
    • Barr PM
    • Fanale MA
    • Knopp MV
    • Noy A
    • Hsi ED
    • Cook JR
    • Lechowicz MJ
    • Gascoyne RD
    • Leonard JP
    • Kahl BS
    • Cheson BD
    • Fisher RI
    • Press OW

Posters

  • Show Details

    P001 (P001) Sequential Brentuximab Vedotin (BV) and Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma (HL): Findings from a Phase II Window Study

    • Evens AM
    • Hamlin PA
    • Nabhan C
    • Advani RH
    • Fanale M
    • Petrich A
    • Smith SM
    • Bociek G
    • Winter J
    • Gordon LI
  • Show Details

    P002 (P002) Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY)

    • Gibb A
    • Pirrie S
    • Linton K
    • Paterson K
    • Davies A
    • Collins G
    • Menne T
    • McKay P
    • Fields P
    • Miall F
    • Nagy E
    • Wheatley K
    • Warbey V
    • Barrington S
    • Radford J
  • Show Details

    P004 (P004) Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-cell Lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): Diagnostic Experiences and Challenges from a Multicenter Study

    • Pilichowska M
    • Pittaluga S
    • Ferry JA
    • Hemminger J
    • Gupta G
    • Kritharis A
    • Gascoyne RD
    • Evens AM
    • Jaffe ES
  • Show Details

    P005 (P005) Hodgkin lymphoma in Sweden since 2000: better survival only in elderly women – a Swedish Lymphoma Registry study

    • Engelbrekt Wahlin B
    • Övergaard N
    • Peterson S
    • Digkas E
    • Glimelius I
    • Lagerlöf I
    • Johansson AS
    • Palma M
    • Hansson L
    • Linderoth J
    • Goldkuhl C
    • Molin D
  • Show Details

    P006 (P006) Advanced Hodgkin Lymphoma in the East of England Cancer Network: A 10 year comparative analysis of outcomes for ABVD and escalated BEACOPP treated patients aged 16–59

    • Collins A
    • Fowler A
    • Karanth M
    • Saha C
    • Russel J
    • Shyamsundar V
    • Docherty S
    • Maw K
    • Padayatty J
    • Hodson A
    • Wimperis J
    • Sadullah  S
    • Grigoropoulos N
    • Uttenthal B
    • Follows G
  • Show Details

    P007 (P007) Superiority of Modified Progression Free Survival (mPFS) to Evaluate Chemotherapy Effectiveness for Advanced Stage Hodgkin Lymphoma

    • Connors JM
    • Gerrie AS
    • Scott DW
    • Sehn LH
    • Villa D
    • Savage KJ
  • Show Details

    P008 (P008) Treatment results for Hodgkin Lymphoma in Brazil: first report from the Brazilian Prospective Hodgkin’s Lymphoma Registry

    • Biasoli I
    • Castro N
    • Delamain M
    • Silveira T
    • Farley J
    • Pinto Simões B
    • Solza C
    • Praxedes M
    • Baiocchi O
    • Gaiolla R
    • Franceschi F
    • Bonamin C
    • Boquimpani C
    • Clementino N
    • Perini G
    • Pagnano K
    • Steffenello G
    • Tabacof J
    • de Freitas Colli G
    • Soares A
    • de Souza C
    • Chiattone CS
    • Milito C
    • Morais JC
    • Spector N
  • Show Details

    P009 (P009) Dose-Dense/Dose-Intense ABVD (dd-di ABVD) in advanced stage Hodgkin's Lymphoma (HL): A Long-Term Follow Up Study

    • Filippo R
    • Luigi A
    • Gino S
    • Pietro F
    • Secondo L
  • Show Details

    P010 (P010) THE SWITCH FROM ABVD TO eBEACOPP AS FRONT-LINE THERAPY FOR HIGH-RISK STAGE III-IV CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS RESULTS IN AN INVERSION OF EVENT-FREE SURVIVAL (EFS) OF PROGNOSTIC GROUPS

    • Aurer I
    • Basic-Kinda S
    • Dujmovic D
    • Radman I
    • Dreta B
    • Dotlic S
    • Galunic-Bilic L
    • Dobrenic M
    • Kralik M
    • Roncevic P
  • Show Details

    P011 (P011) HALO Study: a phase 1/2 clinical trial of Brentuximab-Vedotin and Bendamustin in elderly patients with previously untreated advanced hodgkin lymphoma. Preliminary data

    • Viviani S
    • Fontanet B
    • Rambaldi A
    • Perrot A
    • Patti C
    • Gastaud L
    • Sorasio R
    • Debaigt C
    • Chamorey E
    • Gallamini A
    • Thyss A
  • Show Details

    P012 (P012) Transformation of nodular Hodgkin's lymphoma with lymphocyte predominance to T-cell-rich large B-cell lymphoma

    • Moiseeva TN
    • Al-Radi LS
    • Dorokhina EI
    • Goryacheva SR
    • Margolin OV
    • Magomedova AU
    • Julhakyan HL
    • Kravchenko SK
  • Show Details

    P013 (P013) ABVD AS THE TREATMENT OPTION IN HODGKIN LYMPHOMA WITH LARGE MEDIASTINAL TUMOR

    • Andjelic B
    • Jakovic L
    • Antic D
    • Todorovic M
    • Bila J
    • Djurasinovic V
    • Sretenovic A
    • Vukovic V
    • Jelicic J
    • Smiljanic M
    • Mihaljevic B
  • Show Details

    P014 (P014) PERIPHERAL BLOOD EOSINOPHILIA IS A GOOD RISK FACTOR IN POOR PROGNOSIS GROUP: ADVANCED HODGKIN LYMPHOMA WITH LOW ALC/AMC

    • Jakovic LR
    • Mihaljevic BS
    • Andjelic BM
    • Bogdanovic AD
    • Perunicic Jovanovic MD
    • Bumbasirevic VZ
  • Show Details

    P015 (P015) Lower socioeconomic status is associated with shorter survival in HL patients – an analysis from the Brazilian Hodgkin Lymphoma Registry

    • Biasoli I
    • Castro N
    • Delamain M
    • Silveira T
    • Farley J
    • Pinto Simões B
    • Solza C
    • Praxedes M
    • Baiocchi O
    • Gaiolla R
    • Franceschi F
    • Bonamin C
    • Boquimpani C
    • Clementino N
    • Perini G
    • Pagnano K
    • Steffenello G
    • Tabacof J
    • de Freitas Colli G
    • Soares A
    • de Souza C
    • Chiattone CS
    • Raggio R
    • Milito C
    • Morais JC
    • Spector N
  • Show Details

    P016 (P016) THE IMPACT OF OUTCOME OF INTERIM PET/CT ON ADVANCED HODGKIN LYMPHOMA TREATED WITH BEACOPP-14

    • Medvedovskaya E
    • Leontjeva A
    • Demina E
    • Ryabukhina J
    • Tumyan G
    • Kokosadze N
    • Trofimova O
    • Larionova V
    • Dolgushin M
    • Odzharova A
    • Mukhortova O
    • Aslanidis I
    • Osmanov D
  • Show Details

    P017 (P017) ADVANCED HODGKIN LYMPHOMA – A RISK STRATIFICATION OF ABVD TREATED FEMALES IN GENERATIVE AGE

    • Andjelic B
    • Jakovic L
    • Antic D
    • Todorovic M
    • Bila J
    • Djurasinovic V
    • Sretenovic A
    • Vukovic V
    • Jelicic J
    • Smiljanic M
    • Mihaljevic B
  • Show Details

    P018 (P018) ADVANCED STAGE HODGKIN LYMPHOMA IN MOROCCAN ADULTS: CLINICO-PATHOLOGICAL FEATURES AND THERAPEITIC OUTCOMES

    • Kaddouri W
    • Anoun S
    • Khoubila N
    • Cherkaoui S
    • Lamchahab M
    • Quachouh M
    • Rachid M
    • Madani A
    • Quessar A
  • Show Details

    P019 (P019) General population-derived specific survival applied to Hodgkin Lymphoma

    • Gobbi PG
    • Bellei M
    • Marcheselli L
    • Chisesi T
    • Merli F
    • Galimberti S
    • Iannitto E
    • Luminari S
    • Manni M
    • Stelitano C
    • Musto P
    • Pavone V
    • Vitolo U
    • Federico M
  • Show Details

    P020 (P020) The diagnostics and therapy of Hodgkin lymphoma in pregnancy, the experiences of one center

    • Gahérová L
    • Móciková H
    • Marková J
  • Show Details

    P021 (P021) Difficulties in distinguishing syncytial variant of nodular sclerosis classical Hodgkin’s lymphoma from diffuse large B-cell lymphoma and complete remission after intensive chemotherapy

    • Okatani T
    • Asaoku H
    • Fujiwara M
    • Sato Y
    • Seto M
  • Show Details

    P022 (P022) Systemic Hodgkin's Disease with osseal involvement

    • Banti A
    • Papadakis E
    • Kioumi A
  • Show Details

    P023 (P023) Brentuximab Vedotin Alone and in Combination With Dacarbazine or Bendamustine in Patients Aged ≥60 Years With Newly Diagnosed Hodgkin Lymphoma: Interim Results of a Phase 2 Study

    • Friedberg JW
    • Forero-Torres A
    • Cline-Burkhardt VJM
    • Bordoni RE
    • Patel-Donnelly D
    • Flynn PJ
    • Chen R
    • Fong A
    • Yasenchak CA

Immunotherapy (Basic Science)

Selected for Oral Presentation

  • Show Details

    T007 (T007) Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion

    • Wein F
    • Stock K
    • Hartmann S
    • Hansmann ML
    • Küppers R
  • Show Details

    T008 (T008) CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro-tumor effects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment

    • Casagrande N
    • Borghese C
    • Celegato M
    • Aldinucci D
  • Show Details

    T009 (T009) Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?

    • Nijland M
    • Visser L
    • Veenstra R
    • Kushekhar K
    • van Imhoff G
    • van den Berg A
    • Diepstra A

Posters

  • Show Details

    P059 (P059) Tumor infiltrating HLA-matched CD4+ T cells retargeted against Hodgkin and Reed-Sternberg cells

    • Rengstl B
    • Schmid F
    • Weiser C
    • Döring C
    • Heinrich T
    • Warner K
    • Becker PSA
    • Wistinghausen R
    • Kameh-Var S
    • Werling E
    • Billmeier A
    • Seidl C
    • Hartmann S
    • Abken H
    • Küppers R
    • Hansmann ML
    • Newrzela S

MRD and Prediction

Selected for Oral Presentation

  • Show Details

    T013 (T013) Plasma vesicle-associated miRNAs as therapy response biomarkers in Hodgkin Lymphoma

    • Pegtel DM
    • Drees E
    • van Eijndhoven MAJ
    • Groenewegen NJ
    • van Niele S
    • Prins R
    • Baglio SR
    • van der Voorn H
    • Libregts SFWM
    • Wauben MH
    • de Menezes RX
    • van Weering JRT
    • Nieuwland R
    • Diepstra A
    • van den Berg A
    • de Jong D
    • Zijlstra JM
  • Show Details

    T014 (T014) Mid-treatment TARC and mid-treatment FDG-PET predict for progression free survival in classical Hodgkin Lymphoma

    • Plattel WJ
    • van den Berg A
    • Visser L
    • Glaudemans A
    • Diepstra A
    • van Imhoff GW
  • Show Details

    T015 (T015) A comprehensive analysis of Hodgkin Lymphoma seasonality across various geographic regions

    • Borchmann S
    • Müller H
    • Engert A

Posters

  • Show Details

    P060 (P060) Evaluation of Serum TARC Levels in Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma: Results from the AETHERA Trial

    • Bachanova V
    • Carella A
    • Masszi T
    • Holowiecki J
    • Viviani S
    • Huebner D
    • Hunder N
    • Larsen E
    • Odegard J
    • Onsum M
    • Moskowitz C
  • Show Details

    P061 (P061) Validation of a clinical/biological prognostic model in a large cohort of elderly patients with a classical Hodgkin lymphoma

    • Safar V
    • Morelle M
    • Brice P
    • Rossi C
    • Dupuis J
    • Perrot A
    • Stamatoulas A
    • Garciaz S
    • Carras S
    • Lazarovici J
    • Ghesquieres H
  • Show Details

    P062 (P062) Outcomes and prognostic factors in Hodgkin lymphoma – a single center experience

    • Pinto A
    • Mota D
    • Santos M
    • Guilherme R
    • Gomes M
    • Ribeiro L
  • Show Details

    P063 (P063) Combined prognostic role of TARC protein and PET/CT in patients with Hodgkin lymphoma

    • Husi K
    • Illés A
    • Jóna A
    • Nagy B
    • Fejes Z
    • Barna S
    • Miltényi Z

Pediatric Hodgkin Lymphoma

Selected for Oral Presentation

  • Show Details

    P065 (P065) Joint pediatric Hodgkin and Non-Hodgkin lymphoma study group on grey zone lymphoma in children and adolescents

    • Burkhardt B
    • Makarova O
    • Koerholz D
    • Zimmermann M
    • Mueller S
    • Knoerr F
    • Oschlies I
    • Klapper W
    • Woessmann W
    • Mauz-Koerholz C
  • Show Details

    T016 (T016) Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/A12707)

    • Daw S
    • Punwani S
    • Latifoltojar A
    • Humphries PD
    • Menezes LJ
    • Neriman D
    • Shankar A
    • Popova B
    • Smith P
    • Condne KM
    • Lopes A
    • Taylor SA
  • Show Details

    T017 (T017) Phase III study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children’s Oncology Group

    • Kelly KM
    • Cole PD
    • Chen L
    • Roberts KB
    • Hodgson DC
    • McCarten K
    • Cho SY
    • Schwartz CL
  • Show Details

    T018 (T018) Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis

    • Henderson TO
    • Parsons SK
    • Wroblewski K
    • Chen L
    • Hong F
    • Smith S
    • McNeer J
    • Advani R
    • Gascoyne RD
    • Constine LS
    • Horning S
    • Bartlett NL
    • Shah B
    • Connor JM
    • Leonard J
    • Kahl BS
    • Kelly K
    • Schwartz CL
    • Friedman D
    • Gordon LI
    • Evens AM

Posters

  • Show Details

    P066 (P066) Hodgkin lymphoma in children, adolescents and young adults – a comparative study of clinical presentation and treatment outcome

    • Englund A
    • Glimelius I
    • Rostgaard K
    • Eloranta S
    • Molin D
    • Kuusk T
    • de Nully Brown P
    • Kamper P
    • Smedby KE
    • Hjalgrim H
    • Ljungman G
    • Hjalgrim LL
  • Show Details

    P067 (P067) Pharmacokinetics, Immunogenicity and Safety of Weekly Dosing of Brentuximab Vedotin in Pediatric Patients with Hodgkin Lymphoma

    • Flerlage J
    • Metzger M
    • Panetta JC
  • Show Details

    P068 (P068) Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III clinical trial for advanced stage classical Hodgkin Lymphoma (cHL) in children and adolescents

    • Castellino SM
    • Henderson TO
    • Keller FG
    • Kelly K
    • Curtis R
    • Conti RM
    • Parsons SK
  • Show Details

    P069 (P069) Prediction of primary treatment response and outcome in pediatric Hodgkin lymphoma using digital gene expression profiling

    • Mottok A
    • Johnston RL
    • Chan FC
    • Scott DW
    • Friedman DL
    • Schwartz CL
    • Kelly KM
    • Horton TM
    • Steidl C
  • Show Details

    P070 (P070) Does involved field radiotherapy improve survival rates in pediatric Classic Hodgkin’s Lymphoma?: A retrospective study of 694 children

    • Zaghloul MS
    • Akoush H
    • El Haddad A
    • Attia E
    • Taha H
    • El Wakeel M
    • Omar W
    • El Sayed S
  • Show Details

    P071 (P071) CHIPS as a Predictor of Outcome in Radiated vs. Unradiated HL

    • Schwartz CL
    • Wolden S
    • Constine LS
    • Chen L
    • Friedman DL
  • Show Details

    P073 (P073) Hodgkin lymphoma (HL) in AYA (adolescents and young adults): Results from a single-tertiary-center prospective cohort of 349 patients

    • Bigenwald C
    • Galimard JE
    • Amorim S
    • Thieblemont C
    • Boissel N
    • Resche-Rigon M
    • Brice P
  • Show Details

    P074 (P074) Prognostic value of ‘interim’ positron emission tomography among children with Advanced Hodgkin lymphoma in developing countries; Children Cancer Hospital Egypt experience

    • Khedr R
    • Hamouda A
    • Naguib S
    • Khalaf M
    • Fikry S
    • El Sayed A
    • Taha H
    • Zaghloul MS
    • Attia I
  • Show Details

    P075 (P075) Long-lasting remission in an adolescent with refractory Hodgkin lymphoma after brentuximab vedotin-containing treatment – a case report

    • Fedorova A
    • Markavets A
    • Hushchina L
    • Aleinikova O
  • Show Details

    P076 (P076) Overview and Survival of Pediatric Advanced stage Hodgkin Lymphoma treated in Developing countries; Children Cancer Hospital Egypt Experience

    • Hamouda A
    • Khedr R
    • Naguib S
    • Khalaf M
    • Fikry S
    • El Sayed A
    • Taha H
    • Zaghloul MS
    • Attia I

Postitron Emission Tomography (PET)

Selected for Oral Presentation

  • Show Details

    T019 (T019) Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and